Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Feasibility Trial of Optune for Children With Recurrent or Progressive Supratentorial High-Grade Glioma or Ependymoma, and Feasibility and Efficacy Trial of Optune in Conjunction With Radiation Therapy for Children With Newly Diagnosed DIPG

NCT03033992 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT03033992
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03033992 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Feasibility Trial of Optune for Children With Recurrent or Progressive Supratentorial High-Grade Glioma or Ependymoma, and Feasibility and Efficacy Trial of Optune in Conjunction With Radiation Therapy for Children With Newly Diagnosed DIPG
Lead sponsor
Children's Oncology Group
Phase
Not applicable
Overall status
Active, not recruiting
Start date
April 4, 2017
Completion date
July 22, 2032
Enrollment
80 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse intrinsic pontine glioma, ependymoma, malignant glioma